Skip to content

OPIANT PHARMACEUTICALS, INC.: 10-Q filed 2013-03-18

What OPIANT PHARMACEUTICALS, INC. reported in its quarterly report filed 2013-03-18 (fiscal Q2 2013): 28 published measures, 115 facts as tagged in accession 0001185185-13-000533.

This filing

Form
10-Q (quarterly report)
Filed
2013-03-18
Fiscal period
fiscal Q2 2013
Accession
0001185185-13-000533 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OPIANT PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-01-31175,567USD
At 2012-07-3144,976USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-01-311,202,942USD
At 2012-07-31663,694USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-01-31-1,027,375USD
At 2012-07-31-618,718USD
At 2011-07-31-338,517USD
At 2010-07-31-637,287USD
At 2009-07-31290USD
At 2008-07-31-28,154USD
At 2007-07-31-10,230USD
At 2006-07-3123,375USD
At 2005-07-310USD
At 2004-07-310USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-01-31151,700USD
At 2012-07-3120,423USD
At 2012-01-3147,400USD
At 2011-07-3151,789USD
At 2005-06-200USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-11-01 to 2013-01-31-567,123USD92
2012-08-01 to 2013-01-31-1,637,084USD184
2005-06-21 to 2013-01-31-25,565,979USD2782
2011-11-01 to 2012-01-31-4,577,214USD92
2011-08-01 to 2012-01-31-9,297,314USD184

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-08-01 to 2013-01-31-372,943USD184
2005-06-21 to 2013-01-31-4,859,381USD2782
2011-08-01 to 2012-01-31-575,332USD184

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2012-11-01 to 2013-01-310USD92
2012-08-01 to 2013-01-310USD184
2005-06-21 to 2013-01-310USD2782
2011-11-01 to 2012-01-310USD92
2011-08-01 to 2012-01-310USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-08-01 to 2013-01-31504,220USD184
2005-06-21 to 2013-01-315,011,081USD2782
2011-08-01 to 2012-01-31570,943USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-08-01 to 2013-01-310USD184
2005-06-21 to 2013-01-310USD2782
2011-08-01 to 2012-01-310USD184

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2012-11-01 to 2013-01-31131,717,143shares92
2012-08-01 to 2013-01-31129,906,666shares184
2011-11-01 to 2012-01-3192,755,110shares92
2011-08-01 to 2012-01-3192,755,110shares184

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2012-11-01 to 2013-01-310USD/shares92
2012-08-01 to 2013-01-31-0.01USD/shares184
2011-11-01 to 2012-01-31-0.05USD/shares92
2011-08-01 to 2012-01-31-0.1USD/shares184

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2012-11-01 to 2013-01-310USD92
2012-08-01 to 2013-01-310USD184
2005-06-21 to 2013-01-310USD2782
2011-11-01 to 2012-01-310USD92
2011-08-01 to 2012-01-310USD184

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-08-01 to 2013-01-31446,000USD184
2005-06-21 to 2013-01-312,004,751USD2782
2011-08-01 to 2012-01-31415,833USD184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-11-01 to 2013-01-31-518,442USD92
2012-08-01 to 2013-01-31-1,464,134USD184
2005-06-21 to 2013-01-31-25,350,710USD2782
2011-11-01 to 2012-01-31-4,574,214USD92
2011-08-01 to 2012-01-31-9,280,810USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-01-31151,700USD
At 2012-07-3120,423USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-11-01 to 2013-01-3198,548USD92
2012-08-01 to 2013-01-31243,969USD184
2005-06-21 to 2013-01-31305,358USD2782
2011-11-01 to 2012-01-313,000USD92
2011-08-01 to 2012-01-313,726USD184

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-11-01 to 2013-01-31518,442USD92
2012-08-01 to 2013-01-311,464,134USD184
2005-06-21 to 2013-01-3125,350,710USD2782
2011-11-01 to 2012-01-314,574,214USD92
2011-08-01 to 2012-01-319,280,810USD184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-11-01 to 2013-01-3174,550USD92
2012-08-01 to 2013-01-31123,679USD184
2005-06-21 to 2013-01-31629,848USD2782
2011-11-01 to 2012-01-3156,169USD92
2011-08-01 to 2012-01-31356,169USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-01-31132,761,859shares
At 2012-07-31126,083,416shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-01-3124,431,854USD
At 2012-07-3123,184,094USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2013-01-3123,867USD
At 2012-07-3124,553USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2013-01-310USD
At 2012-01-310USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2012-11-01 to 2013-01-31-567,123USD92
2012-08-01 to 2013-01-31-1,663,096USD184
2005-06-21 to 2013-01-31-25,591,991USD2782
2011-08-01 to 2012-07-31-12,421,188USD366
2011-11-01 to 2012-01-31-4,577,214USD92
2011-08-01 to 2012-01-31-9,297,314USD184
2010-08-01 to 2011-07-31-9,435,787USD365
2009-08-01 to 2010-07-31-2,016,710USD365
2008-08-01 to 2009-07-3128,444USD365
2007-08-01 to 2008-07-31-17,924USD366
2006-08-01 to 2007-07-31-33,605USD365
2005-08-01 to 2006-07-31-32,125USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-11-01 to 2013-01-31443,892USD92
2012-08-01 to 2013-01-311,340,455USD184
2005-06-21 to 2013-01-3124,681,847USD2782
2011-11-01 to 2012-01-314,518,045USD92
2011-08-01 to 2012-01-318,924,641USD184

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2012-08-01 to 2013-01-31686USD184
2005-06-21 to 2013-01-313,583USD2782
2011-08-01 to 2012-01-31508USD184

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2012-11-01 to 2013-01-31-48,681USD92
2012-08-01 to 2013-01-31-172,950USD184
2005-06-21 to 2013-01-31-215,269USD2782
2011-11-01 to 2012-01-31-3,000USD92
2011-08-01 to 2012-01-31-16,504USD184

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-08-01 to 2013-01-310USD184
2005-06-21 to 2013-01-313,936,449USD2782
2011-08-01 to 2012-01-31652,500USD184

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-08-01 to 2013-01-314,988USD184
2005-06-21 to 2013-01-3160,485USD2782
2011-08-01 to 2012-01-31-63,136USD184

Inspect the source

Entity
OPIANT PHARMACEUTICALS, INC. / CIK 0001385508
Captured
SEC response SHA-256
2364e629461ca2a795db263ee8044ac545282f6ca3e3ea28eb9ce90156d0a955

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385508.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))